# Progress Note 01 — Initial plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Marilyn Monroe (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML002-SYN
- Date: 2026-06-15
- Fictional facility: St. Posthumous Health Center
- Fictional author: Joanna Whitlock, MD
- Calendar frame: modern shifted

## Subjective

The patient participates in this fictional visit for new patient with severe painful periods and pelvic pain: history and pelvic examination, suspected endometriosis, first-line hormonal and anti-inflammatory treatment, a pain plan without opioids or sedatives, and a depression and anxiety screen. **S**

## Objective

White cells: 6.4 10*3/uL; Hemoglobin: 12.2 g/dL; Platelets: 262 10*3/uL; PHQ-9: 12; GAD-7: 8; Pelvic pain, worst in the past week (0 to 10): 8. All results are synthetic.

BP 112/70 mmHg; pulse 76 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 99% on room air; weight 56 kg; BMI 20.3 kg/m². All vital signs are synthetic.

## Assessment

Active problems: Severe painful periods since her teens, worse over the past three years, with pelvic pain between periods, deep pain with intercourse, and painful bowel movements during periods; she misses work for two or three days each cycle. Tender, slightly fixed retroverted uterus with tenderness and fullness in the left adnexa and along the left uterosacral ligament. Suspected endometriosis; transvaginal ultrasound and gynecology consultation booked; Major depressive disorder, single episode, moderate: about two months of low mood, poor sleep on painful nights, low energy, guilt about missed work, and poor concentration (PHQ-9 12, item 9 scored 0; GAD-7 8); Mood Disorder Questionnaire negative; no thoughts of suicide or self-harm. Strengths and supports remain part of the care plan. **S**

## Medication changes

- Started: Naproxen 500 mg oral tablet, one tablet by mouth twice daily with food, from two days before an expected bleed until the third day, and for pain flares; no more than 10 days a month **S**
- Started: Ethinyl estradiol 0.02 mg and norethindrone acetate 1 mg oral tablet, one tablet by mouth daily, taken continuously without a pill-free week **S**

## Plan

- First-line treatment for suspected endometriosis without waiting for a diagnosis: naproxen with food for pain days, and a combined estrogen and progestin pill taken continuously to stop the periods, after a negative pregnancy test and a check for reasons to avoid estrogen (migraine with aura, smoking over 35, clotting history, high blood pressure). Guideline: Practice Bulletin No. 114: Management of Endometriosis (2010); ESHRE guideline: endometriosis (2022); U.S. Medical Eligibility Criteria for Contraceptive Use, 2024 (2024) **S**
- Gynecology consultation for suspected endometriosis: diagnosis, the role and timing of surgery, and fertility counseling for a woman who wants children. Guideline: Practice Bulletin No. 114: Management of Endometriosis (2010); ESHRE guideline: endometriosis (2022) **S**
- Transvaginal ultrasound by an experienced sonographer, looking for endometriomas and deep nodules; CA-125 not used to diagnose endometriosis; gonorrhea and chlamydia tests and a urinalysis to exclude other causes. Guideline: ESHRE guideline: endometriosis (2022); Chronic Pelvic Pain: ACOG Practice Bulletin, Number 218 (2020) **S**
- A pain plan that avoids opioid and sedative accumulation: no opioid, benzodiazepine or sleep-medicine prescription, the prescription monitoring program checked, diphenhydramine stopped, leftover medicines returned, heat and regular walking, and cognitive behavioral therapy for insomnia. Guideline: Chronic Pelvic Pain: ACOG Practice Bulletin, Number 218 (2020); CDC Clinical Practice Guideline for Prescribing Opioids for Pain, United States, 2022 (2022) **S**
- Depression care: cognitive behavioral therapy with the clinic's behavioral health clinician, the PHQ-9 and GAD-7 at each visit, an antidepressant to be discussed if the PHQ-9 has not fallen by half at eight to twelve weeks, a structured safety assessment and plan, the 988 Suicide & Crisis Lifeline, and safety review at every visit. Guideline: Depression and Suicide Risk in Adults: Screening (2023); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026) **S**
